Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple negative breast cancer
- VernacularTitle:紫杉类联合蒽环类的新辅助化疗方案治疗三阴乳腺癌的疗效及预后
- Author:
Bo ZHOU
;
Fei XIE
;
Siyuan WANG
;
Deqi YANG
- Publication Type:Journal Article
- Keywords:
breast neoplasms;
neoadjuvant chemotherapy;
triple negative breast neoplasms;
prognosis
- From:China Oncology
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Triple-negative breast cancer(TNBC) is a high risk breast cancer that lacks the benefit from molecular targeted therapy.The purpose of this study was to compare the response to neoadjuvant taxanes and anthracyclines chemotherapy and survival in patients with TNBC and non-TNBC.Methods:One hundred and thirty-eight patients treated with 4 cycles of neoadjuvant taxanes,and anthracyclines chemotherapy were included in this retrospective study.TNBC is defined as the lack of estrogen receptor(ER),progesterone receptor(PR),and human epidermal growth factor receptor 2(Her-2) expression by immunohistochemistry method.The clinical and pathologic response and neoadjuvant taxane and anthracycline chemotherapy,and the relationships of response and survival between TNBC and non-TNBC were analyzed.Results:Of the 138 patients,37(26.8%) were TNBC and 101(73.2%) were non-TNBC.The overall response rate(OR)was 85.5%(118/138),including 35.5% clinical complete response(cCR) and 50.0% clinical partial response(cPR).The pathologic complete response(pCR) was 21.7%.The cCR and pCR were 51.4% and 45.9% in patients with TNBC,significantly higher than patients with non-TNBC respectively(29.7% and 12.9%)(P0.05).In contrast,TNBC patients with residual disease after neoadjuvant chemotherapy had worse 5-year DFS and OS compared with non-TNBC(P
